Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT02067182

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02067182
  • EudraCT 2013-003492-35
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02067182. Randomized; no masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2020-09-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
Acronym
ODIn-AF
Condition
Cardioembolic Events
Condition
Oral Anticoagulation
Intervention (Drug)
Dabigatran
Lead sponsor
Georg Nickenig (class: other)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct02067182
Content hash
165dfdc55b7a5254f417a820f19ae55cce33709ded0c4dad7162fc33728f1b93